CA2929688C - Solid compositions of triglycerides and uses thereof - Google Patents

Solid compositions of triglycerides and uses thereof Download PDF

Info

Publication number
CA2929688C
CA2929688C CA2929688A CA2929688A CA2929688C CA 2929688 C CA2929688 C CA 2929688C CA 2929688 A CA2929688 A CA 2929688A CA 2929688 A CA2929688 A CA 2929688A CA 2929688 C CA2929688 C CA 2929688C
Authority
CA
Canada
Prior art keywords
less
pharmaceutical composition
poly
triheptanoin
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2929688A
Other languages
English (en)
French (fr)
Other versions
CA2929688A1 (en
Inventor
John KLOPP
Gabrielle MORRIS
Emil Kakkis
Steven Jungles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultragenyx Pharmaceutical Inc
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53058066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2929688(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Priority to CA3197154A priority Critical patent/CA3197154A1/en
Publication of CA2929688A1 publication Critical patent/CA2929688A1/en
Application granted granted Critical
Publication of CA2929688C publication Critical patent/CA2929688C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2929688A 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof Active CA2929688C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3197154A CA3197154A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14
US61/904,369 2013-11-14
PCT/US2014/065693 WO2015073816A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3197154A Division CA3197154A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Publications (2)

Publication Number Publication Date
CA2929688A1 CA2929688A1 (en) 2015-05-21
CA2929688C true CA2929688C (en) 2023-06-13

Family

ID=53058066

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2929688A Active CA2929688C (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof
CA3197154A Pending CA3197154A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3197154A Pending CA3197154A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Country Status (18)

Country Link
US (6) US20160243071A1 (https=)
EP (2) EP3782610A1 (https=)
JP (4) JP2017501972A (https=)
KR (1) KR102291310B1 (https=)
CN (2) CN105764497A (https=)
AR (2) AR099353A1 (https=)
AU (1) AU2014348470B2 (https=)
CA (2) CA2929688C (https=)
CL (1) CL2016001130A1 (https=)
ES (1) ES2833294T3 (https=)
IL (1) IL245588B (https=)
MX (2) MX383005B (https=)
MY (1) MY177028A (https=)
PE (1) PE20161024A1 (https=)
PH (1) PH12016500821A1 (https=)
RU (1) RU2016123169A (https=)
TW (1) TWI640327B (https=)
WO (1) WO2015073816A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764497A (zh) * 2013-11-14 2016-07-13 奥特吉尼克斯制药公司 三酸甘油酯的固体组合物及其用途
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
CA3110724A1 (en) 2018-08-27 2020-03-05 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337596A (en) 1965-02-18 1967-08-22 Procter & Gamble Synthesis of mixed glycerides
JPS5215834A (en) 1975-07-12 1977-02-05 Ajinomoto Kk Method of producing food composition
US4753963A (en) 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
JPH07102106B2 (ja) 1987-06-10 1995-11-08 日清製粉株式会社 経口，経管栄養食の製造法
KR100318295B1 (ko) 1989-07-05 2002-11-16 가부시키가이샤 저펜에너지 냉각윤활제
EP0421581A1 (en) 1989-10-03 1991-04-10 Warner-Lambert Company Chewable spray dried spheroidal microcapsules and wax coated microcapsules and methods for preparing same
JPH0692848A (ja) 1992-09-11 1994-04-05 Sagami Chem Res Center 糖尿病治療用乳剤
JPH06145688A (ja) 1992-11-10 1994-05-27 Nippon San Sekiyu Kk 冷凍機用潤滑油組成物
JP2800610B2 (ja) * 1992-12-15 1998-09-21 不二製油株式会社 水中油型乳化物の製造法
JP3522843B2 (ja) * 1994-07-29 2004-04-26 昭和産業株式会社 リポ製剤
US5746933A (en) 1994-11-07 1998-05-05 Nippon Oil Co., Ltd. Lubricating oil and composition for refrigerating machine, and refrigerating machine
DE69612755T2 (de) * 1995-02-07 2001-08-23 Brusilow Enterprises, Llc Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
US5698210A (en) 1995-03-17 1997-12-16 Lee County Mosquito Control District Controlled delivery compositions and processes for treating organisms in a column of water or on land
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
JP3391798B2 (ja) 1995-09-25 2003-03-31 花王株式会社 エステル化合物及び潤滑油組成物
US5908631A (en) * 1997-02-27 1999-06-01 L'oreal S.A. Monohydric alcohol-free composition for topical use comprising solubilized ethylcellulose
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6278006B1 (en) 1999-01-19 2001-08-21 Cargill, Incorporated Transesterified oils
WO2000045649A1 (en) * 1999-02-05 2000-08-10 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
DE60130083T2 (de) 2000-10-16 2008-05-15 Nof Corp. Herstellung von Estern für die Verwendung als Basisschmieröl
JP4282289B2 (ja) 2002-08-29 2009-06-17 株式会社ジャパンエナジー 流体軸受用潤滑油及びそれを用いた流体軸受
AU2003261928A1 (en) 2002-09-05 2004-03-29 The Nisshin Oillio Group, Ltd. Agents, foods and drinks controlling lipid metabolism
US8399515B2 (en) * 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005120484A1 (ja) 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
EP1773317A4 (en) 2004-07-02 2012-10-03 Baylor Res Inst METHOD OF TREATING OVERLOADING DISEASE DUE TO ACCUMULATION OF GLYCOGENES OR POLYSACCHARIDES
WO2006099325A2 (en) 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
BRPI0608691A2 (pt) * 2005-03-10 2010-12-07 3M Innovative Properties Company composição antimicrobiana, e, métodos para matar ou inativar microorganismos em tecido da mucosa de um mamìfero, para tratar uma lesão ou ferimento infectado, para descolonização de microorganismos, para proporcionar eficácia antimicrobiana residual sobre uma superfìcie e para tratar uma condição
FR2894822B1 (fr) 2005-12-20 2011-11-18 Pf Medicament Composition pharmaceutique contenant des acides gras omega-3
EP1991208A2 (en) 2006-02-10 2008-11-19 SportsCom Danmark ApS Coated tablets, their methods of preparation, and related uses
JP5099808B2 (ja) 2006-05-29 2012-12-19 独立行政法人農業・食品産業技術総合研究機構 脂質代謝改善用組成物
CN101730475A (zh) 2007-05-08 2010-06-09 帝斯曼知识产权资产管理有限公司 体重维持和机体组成
JP5296366B2 (ja) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 医薬品用持久力向上剤および持久力向上用医薬品
CA2719246A1 (en) 2008-03-26 2009-10-01 Taro Pharmaceuticals North America, Inc. Stabilizing lipid compositions for oral pharmaceutical agents
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
ES2695534T3 (es) 2008-08-29 2019-01-08 Horizon Therapeutics Llc Métodos de tratamiento usando fármacos de captación de amoniaco
KR20120129898A (ko) 2009-12-30 2012-11-28 베일러 리서치 인스티튜트 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법
JP2013528648A (ja) * 2010-06-14 2013-07-11 ベイラー リサーチ インスティテュート 成人ポリグルコサン小体病（ａｐｂｄ）を処置するためのトリヘプタノイン食
US8932646B2 (en) 2010-06-18 2015-01-13 Bausch & Lomb Incorporated Peroxide contact lens care solution
CN101919453B (zh) * 2010-08-16 2013-04-10 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
JP5820256B2 (ja) 2011-02-10 2015-11-24 株式会社ファンケル 自己乳化製剤
WO2013012699A2 (en) 2011-07-15 2013-01-24 3M Innovative Properties Company Polyurethane based coating compositions
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
JP6080269B2 (ja) 2012-02-15 2017-02-15 日清オイリオグループ株式会社 飼料用組成物、飼料、及び飼料の製造方法
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
EP2838522B1 (en) * 2012-04-16 2024-02-21 University of Pittsburgh - Of the Commonwealth System of Higher Education Phenylbutyrate for the treatment of medium-chain acyl-coa dehydrogenase deficiency
CA2894456C (en) 2012-12-13 2022-06-28 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
AU2014296415B2 (en) 2013-07-31 2019-11-21 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of fatty acid metabolism disorders
CN105764497A (zh) 2013-11-14 2016-07-13 奥特吉尼克斯制药公司 三酸甘油酯的固体组合物及其用途
WO2020014428A1 (en) 2018-07-11 2020-01-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids

Also Published As

Publication number Publication date
EP3068383B1 (en) 2020-09-16
JP2020111585A (ja) 2020-07-27
US20250120934A1 (en) 2025-04-17
MY177028A (en) 2020-09-02
US20230181513A1 (en) 2023-06-15
TWI640327B (zh) 2018-11-11
TW201609189A (zh) 2016-03-16
AR099353A1 (es) 2016-07-20
EP3782610A1 (en) 2021-02-24
ES2833294T3 (es) 2021-06-14
AU2014348470A1 (en) 2016-05-26
CA2929688A1 (en) 2015-05-21
EP3068383A4 (en) 2017-11-08
CN113181158A (zh) 2021-07-30
KR102291310B1 (ko) 2021-08-23
PH12016500821A1 (en) 2016-06-13
PE20161024A1 (es) 2016-11-10
MX383005B (es) 2025-03-13
AR130666A2 (es) 2025-01-08
JP2024129109A (ja) 2024-09-26
EP3068383A1 (en) 2016-09-21
US20200069631A1 (en) 2020-03-05
US20160243071A1 (en) 2016-08-25
IL245588B (en) 2021-08-31
MX2021001790A (es) 2021-04-19
US20250120936A1 (en) 2025-04-17
AU2014348470B2 (en) 2020-01-30
US20250120935A1 (en) 2025-04-17
MX2016006329A (es) 2016-09-06
KR20160084407A (ko) 2016-07-13
CA3197154A1 (en) 2015-05-21
CL2016001130A1 (es) 2017-01-20
JP2022107017A (ja) 2022-07-20
IL245588A0 (en) 2016-06-30
US12551461B2 (en) 2026-02-17
JP2017501972A (ja) 2017-01-19
CN105764497A (zh) 2016-07-13
RU2016123169A (ru) 2017-12-19
WO2015073816A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
US12551461B2 (en) Compositions of triglycerides and uses thereof
CN103889455B (zh) 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂
AU2013304795B2 (en) Solid pharmaceutical preparation containing levothyroxine
WO2010075537A1 (en) Formulations comprising vitamin d or derivatives thereof
CN108430460A (zh) 包含度他雄胺和丙二醇单月桂酸酯的药物组合物及其制备方法
CN104758265A (zh) 一种雷诺嗪缓释片药物组合物及其制备方法
US11938117B2 (en) Magnesium biotinate compositions and methods of use
TW201035089A (en) Pharmaceutical composition
TW202339709A (zh) 微粒化索拉貝隆(solabegron)之組成物及使用方法
RS56830B1 (sr) Farmaceutska kompozicija koja sadrži (1r,4r)-6’-fluoro-n,n-dimetil-4-fenil-4’,9’-dihidro-3’h-spiro[cikloheksan-1,1’-pirano [3,4,b]indol]-4-amin i meloksikam
HK40056892A (en) Solid compositions of triglycerides and uses thereof
KR20200005576A (ko) 호모타우린 및 이의 염의 제형
CN105902490A (zh) 一种头孢克洛复方固体制剂及其制备方法
CN105596304B (zh) 用于减缓周边血管疾病病患间歇性跛行症状的属喹啉酮衍生物的西洛他唑的新颖调配物
BR112016010583B1 (pt) Composição, composição farmacêutica e uso das mesmas
RU2833428C1 (ru) Пероральная композиция x842
RU2833428C9 (ru) Пероральная композиция x842
WO2012045863A1 (en) Pharmaceutical compositions comprising glimepiride and polyethylene glycol castor oil
EP0412877A1 (fr) Nouvelle forme galénique orale améliorant la biodisponibilité
WO2023194433A1 (fr) Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales
CN115666532A (zh) 含有利马前列素的缓释制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190930

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024